Pear Therapeutics Stock

peartherapeutics.comBioTechFounded: 2013Funding to Date: $139MM

Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

Register for Details

For more details on financing and valuation for Pear Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Corey McCann Ph.D
Co-Founder, President, Chief Executive Officer & Board Member
Christopher Guiffre JD
Chief Operating Officer & Chief Financial Officer
Alex Waldron
Chief Commercial Officer
Jeremy Gilbert
Chief Product Officer
Stephen Smith JD
Co-Founder & Executive Vice President of Corporate Development
Yuri Maricich MD
Chief Medical Officer & Head of Clinical Development
Beth Rogozinski
Chief Content Advisor
Walter Greenleaf Ph.D
Chief Science Advisor
Jeffrey Lieberman
Advisor

Board Members

Andrew Schwab
5AM Ventures
Corey McCann Ph.D
Delaine Cheong
Temasek Holdings
Hu Hongjie
Temasek Holdings
Jamil Beg
5AM Ventures
Jeremy Sohn
John Harris
JAZZ Venture Partners
Thomas Shehab MD
Arboretum Ventures
Timothy Petersen
Arboretum Ventures
Zack Lynch
JAZZ Venture Partners

Other companies like Pear Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

The latest funding was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Partners, The Bridge Builders Collaborative and EDBI.